Abstract 246P
Background
To study the main causes of neglect of advanced cervical cancer (CC) in Uzbekistan based on the results of a survey of advanced stage cervical cancer patients. The questionnaire was analyzed in 3 directions: “patient delay”, “doctor delay”, “delay of treatment”.
Methods
200 patients with advanced cervical cancer were included in the analysis, including: IIA-B stage-17%; IIIA-B stage 80%; IVA stage - 3%. Descriptive analyses were provided with the WHO questionnaire, adopted for local use, which should explore the possible barriers of early detection of cervical cancer.
Results
In the questionnaire analysis, the following results were obtained in the direction of “doctor delay”: 1. Which doctor did you talk about the symptoms of the disease? General practioner - 8%, gynecologist - 90%, private doctor - 2%; 2. Prior to the establishment of diagnosis contacted doctor: once - 22%, twice - 29%, 3 times and more - 49%. 3. How many times did you have a doctor before starting chemotherapy: Never - 86%, 3 or more times 14%. 4. Some aspects of the treatment surprised patients, no one warned: yes-56%, no-54%; I can easily ask doctor about the disease: Yes-45%, no-55%. 5. Appeal to the doctors before the establishment of diagnosis: twice - 29%, 3 and more time - 49%; To which specialist did you first tell about the symptoms of the disease: Physician - 97%, nurse - 2%, healer - 1%. 6. How many times have been in doctor with relatives: Never -37%; once - 19%; twice - 24%; 3 and more times - 20%. 7. Where you underwent the necessary examinations: State clinic - 70%; private clinic - 30%.
Conclusions
The main reasons for the neglect of cervical cancer in the direction of “doctor delay” are: Weak awareness of general practitioners; Unsatisfactory in forming patients about the severity of the disease, inability to enter the patient's trust; Absence or low level of psychological support of patients; Problems of timely referral of patients to an oncologist; Problems of deontology in the chain: doctor-diagnosis-patient. Elimination of the above-mentioned main causes will lower the incidence and mortality from cervical cancer and improve treatment outcomes, preventing disability of women.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Nargiza Zakhirova.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract